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Azithromycin (AZM) therapeutic failure and relapses of patients treated with generic formulations have been observed in clinical
practice. The main goal of this research was to compare in a preclinical study the serum exposure and lung tissue concentration
of two commercial formulations AZM-based in murine model. The current study involved 264 healthy Balb-C. Mice were divided
into two groups (𝑛 = 44): animals of Group A (reference formulation -R-) were orally treated with AZM suspension at 10mg/kg
of b.w. Experimental animals of Group B (generic formulation -G-) received identical treatment than Group A with a generic
formulation AZM-based. The study was repeated twice as Phase II and III. Serum and lung tissue samples were taken 24 h post
treatment. Validated microbiological assay was used to determine the serum pharmacokinetic and lung distribution of AZM. After
the pharmacokinetic analysis was observed, a similar serum exposure for both formulations of AZM assayed. In contrast, statistical
differences (𝑃 < 0.001) were obtained after comparing the concentrations of both formulations in lung tissue, being the values
obtained for AUC and Cmax (AZM-R-) +1586 and 122%, respectively, than those obtained for AZM-G- in lung. These differences
may indicate large differences on the distribution process of both formulations, which may explain the lack of efficacy/therapeutic
failure observed on clinical practice.
1. Introduction
Azithromycin (AZM) is a macrolide antibiotic that chemi-
cally differs from erythromycin by methyl-substituted nitro-
gen atom at position 9a in the macrolide ring. AZM is com-
posed by fifteen-membered ring structure having two sugar
moieties, several hydroxyl groups, two tertiary amino groups,
and one oxycarbonyl group (Figure 1). It is only slightly
soluble in water but highly soluble in lower alcohols and yet
shows low viscosity in these solvents. These chemical modi-
fications derived from the primary molecule (erythromycin)
have produced profound modifications on the AZM in vitro
spectrum, potency, and superior stability to acid environment
[1]. In vivo studies demonstrated that AZM concentrations
are highly accumulated in alveolar macrophages and lung
being 100% higher than those reported in plasma [1, 2] by
which this has largely been recommended for the treatment
of some respiratory diseases, sexually transmitted diseases,
some skin diseases, and otitis media. Among other reasons,
this antibiotic formulated mainly as suspension or tablets is
used in human and in veterinary medicine.
The need of decreasing the cost of the treatments moves
the replacing of bioequivalent innovator drugs with generic
drugs. Around the world, the replacement is promoted in
some case of disease when the generic drugs are bioequiv-
alent with his respective innovator drugs [3, 4]. However,
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Figure 1: Chemical structure of Azithromycin.
therapeutic failure and adverse effects in the use of generic
drugs in humans in specific diseases like antiepileptic drugs
have been reported [4, 5].
Interestingly, AZM was recently reported as a new chiral
selector in capillary electrophoresis studies, having multiple
stereogenic centers [6]. The presence of multiple chiral cen-
ters and different functional groups may undergo multiple
interactions with the analyte enantiomeric molecules for chi-
ral recognition in a similar way to other macrocyclic antibi-
otic chiral selectors [6].
In recent years, the drugs stereochemistry became in a
significant issue for the pharmaceutical industry. The ster-
eoisomers interact differently with the macromolecules in
the body, while waiting for the process of passive diffusion/
transporters uptake into cell membranes which is equivalent
for both moieties [7–9]. Thus, differences in active transport
in serum secretion protein-binding, metabolism, and phar-
macological effects for both molecules may have differences
for achieving the biophase. Such steroisomers frequently dif-
fer in terms of their biological activity and pharmacokinetic
(PK) profiles and the use of such mixtures contributes to the
adverse effects of the drug particularly if they are associated
with the inactive or less active isomer [10, 11].
Most drugs and drug-like molecules are likely to bind
to multiple transporters, for example; drugs are known to
interact with no fewer than six targets and many proteins are
known to interact with hundreds of drugs to get the biophase
[12]. However, also it is worth to mention the interaction
drug-drug with proteins, such as transporters, rather than
phospholipids, becoming on the area of adverse effects [12].
Therapeutic failure and relapses of patients treated with
generic formulations have been observed in some hospitals
[13, 14]. However, those products were approved for commer-
cialization, based on pharmacokinetic/bioequivalence stud-
ies. Similar clinical observations were seen in veterinary clin-
ical practice using generic human formulations in Rhodococ-
cus equi pneumonia diagnosed foals. For that reason, we
hypothesized that the lung distribution of the active principle
(API) and its consequent efficacy of two bioequivalent formu-
lations AZM-based are different.
The inconvenience of assessing AZM in lung parenchyma
via biopsy in live mammals is derived in the current study.
The main goal of this research was to compare in a pre-clin-
ical study the AZM serum exposure and lung tissue con-
centration of two commercial formulations AZM-based in
murine model.
2. Materials and Methods
2.1. Bacterial Strains. Bacterial strains usedwere:Kocuria rhi-
zophila (ex-Micrococcus luteus) ATCC 9341 an azithromycin
susceptible strain.
2.2. Experimental Design. The current study involved 264
healthy Balb-C mice weighing 18–20 g. Mice were normally
fed having free access to water. The experiment was designed
using 88 experimental animals (Phase I) and repeated twice
(Phases II and III). For each experimental Phase, Balb-Cmice
were divided in two groups (𝑛 = 44): animals of Group A
(reference formulation -R-) were orally treated (via cannula)
with AZM suspension at 10mg/kg of body weight (Zithro-
max, Pfizer, Argentina). Experimental animals of Group B
(generic formulation -G-) received identical treatment to that
of Group A with a generic formulation AZM-based (Azitro-
micina Richet, Richet S.A, Argentina).
The whole experiment was performed under the policies
of Animal Welfare of UNCPBA Veterinary Faculty (http://
www.vet.unicen.edu.ar).
Experimental animals were humanely euthanized. Serum
and lung tissue samples were taken as follows: time 0 (pre
treatment) and after treatment at 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12,
and 24 h. Each sampling timepoint per experimental phase
is represented by 4 animals. After samples collection, the
blood was centrifuged at 1.5 ×g by 10min and the serum was
stored at −80∘C, until analysis. Lung samples were taken and
wrapped in aluminium paper upon being stored at −80∘C.
2.3. Microbiological Assay. The concentration of azithromy-
cin (AZM) was measured in serum and lung tissue using
the microbiological assay, according to Breier et al. [15]. The
strain Kocuria rhizophila (ex-Micrococcus luteus) ATCC 9341
was used as the indicator. Briefly, an aliquot (200𝜇L) of
Kokuria rhizophila was inoculated in 3mL of brain-heart
infusion (BHI) broth and incubated at 35∘C for 24 h. After-
wards, a suspension with a viable count of 1 × 108 CFU/mL
was prepared; 200𝜇L of this suspension was added to a tem-
pered tube containing 7mL of soft-agarMueller Hinton (Lab.
Britania; Argentina) and distributed evenly in Petri dishes
with 13mL of Mueller Hinton agar (Lab. Britania; Argentina,
15.5 g/L). The dishes were allowed to solidify and wells were
punched and filled with 100𝜇L from each serum sample. In
lung tissue, each one was weighted (0.01 g) and emulsified in
1mL of sterile distilled water in a glass-mortar, the resulting
homogenate was sonicated and 100 𝜇L was placed in the
respective well. Agar dishes were incubated for 24 hours at
35∘C. A standard curve was done with a solution of AZM
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(Pfizer, US) between 0.025–5 𝜇g/mL for serum and 0.150 to
150𝜇g/g for lung tissue samples.The results shown, represent
the average of three experiments.
2.4. Statistical Analysis. Statistical analysis was performed
using the nonparametric Mann-Whitney test, after compar-
ing the results of the 3 phases of study.
2.5. Pharmacokinetic Analysis.The concentration versus time
curves for AZM in serum and lung tissue obtained from
each individual experimental animal after oral treatmentwith
AZM was fitted by a PK Solution Software package (Sum-
mit Research Services, Ashland, OH, USA). Serum and lung
tissue concentrations best fitted to a biexponential curve (𝑟2 =
0.9880 and 𝑟2 = 0.998).Themaximum concentrations (𝐶max)
and time to 𝐶max (𝑇max) of AZM in serum and lung after
oral administration were extrapolated from the plotted con-
centration time curve as the average of 4 animals per point/
phase (12 animals average per point). Trapezoid AUCs were
calculated according to Gibaldi and Perrier [16].
3. Results and Discussion
3.1. Microbiological Assay. A bioassay method was used in
this study to determine the concentrations of AZM serum
and lung compartments after a single-dose oral administra-
tion. Since the microbiological assay seems to measure the
total microbiological action, it was considered the more
appropriate tomeasure the in vivo drug concentrations effect-
iveness, with the goal of correlating with the clinical and
bacteriological cure observed on the clinical practice [15].
The assay was linear between 0.025 and 5.0 𝜇g/mL for
serum and 0.150 and 150 𝜇g/g for lung tissue samples. Cali-
bration curves yielded a correlation coefficient of 0.998 and
0.987 for serum and lung, respectively. It was assessed by
assaying samples of murine serum and lung tissue sample, at
three different concentrations, during the same day and three
different days under the same experimental conditions. Intra-
assay and interassay coefficients of correlation were lower
than 3%.
3.2. Pharmacokinetic in Serum and Lung Tissue Distribution
Studies. After analysis of primary PK parameters (Table 1)
was observed, a similar serum exposure for the two formu-
lations of AZM assayed based in similar AUC values (AUC
= 34.5 𝜇g⋅h/mL -AZM-R- and 33.3 𝜇g⋅h/mL -AZM-G-). No
differences in 𝐶max and 𝑇max were observed in serum after
both treatments (Table 1 and Figure 2). These outcomes
indicated that the absorption process after both treatments
was not affected. In contrast, statistical differences 𝑃 < 0.001
were obtained after comparing the concentrations of both
formulations in lung tissue. Thus, the values obtained for
AUC and 𝐶max for the AZM-R- formulation increase by
more 1586 and 122%, respectively, than those values obtained
for AZM-G-formulation. The latter also correlates with the
longer half life of elimination obtained for AZM-R (3.78 h)
when comparedwith the AZM-G formulation (0.22 h).These
statistical differences on the PK parameters reported in
Table 1 and Figure 3 may indicate large differences on the
Table 1: Comparative pharmacokinetic parameters of serum and
lung of both formulations azithromycin-based assayed.
PK parameter AZM reference AZM generic
Serum
𝐶max (𝜇g/mL) 2.40 ± 0.10 2.60 ± 0.23
𝑇max (h) 1.00 ± 0.00 2.50 ± 0.00
AUC (𝜇g ⋅ h/mL) 34.5 ± 2.50 33.3 ± 1.50
SDP (h) 0.5–2.4 0.5–24
Lung
𝐶max (𝜇g/mL) 45.0 ± 3.00 101 ± 10.4
∗∗∗
𝑇max (h) 0.50 ± 0.00 0.50 ± 0.00
AUC (𝜇g ⋅ h/mL) 1022 ± 53.0 60.6 ± 5.00∗∗∗
LDP (h) 0.5–2.5 0.5–24
PK Values are showed as the average of the 3 different assays.
∗∗∗Values statistically different to the Reference group at 𝑃 < 0.001.
𝐶max: maximum serum concentration peak, 𝑇max: time at 𝐶max; AUC: area
under the concentration versus time curve; SDP: Serum Detection Period;
LDP: Lung Detection Period.
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Figure 2: Comparative serum exposure concentrations (Mean ±
SD) of two commercial formulations Azithromycin-based after
given orally at 10mg/kg as suspension in mice. Each point plotted
in the curve is the average of 12 experimental animals.
distribution process of both formulations, whichmay explain
the lack of efficacy/therapeutic failure observed on the clinical
practice for the AZM-G-formulation.
Macrolide antibiotics like AZM and Clarithromycin
(CLR) are large molecular weight compounds and are sub-
strates for apically polarized efflux transporters such as P-
glycoprotein, which can potentially restrict intestinal absorp-
tion. However, despite these undesired physicochemical and
biopharmaceutical properties, AZM and CLR exhibit mod-
erate to excellent p.o. bioavailability in preclinical species and
humans. Intestinal uptake transporters, such as organic anion
transporting polypeptides (OATPs), can facilitate the uptake
of drugs that are substrates and hence increase p.o. absorption
[17].
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Figure 3: Comparative lung tissue concentrations of two commer-
cial formulations Azithromycin-based after given orally at 10mg/kg
as suspension in mice: each point plotted in the curve is the average
of 12 experimental animals.
It is pivotal to recognize some of the factors than it can
alter the outcome of PK studies and therefore potentially
altering the pharmacological response. When compared the
serum exposure of AZM-R- with AZM-G-, neither PK dif-
ferences nor absorption process was observed after the race-
mic formulation administration (Table 1, Figure 2).The AUC
values and the similar displaying curves were obtained, let-
ting us hypothesize that, specifically, AZM could not exhibit
enantio-selective absorption when probably a chiral- imbal-
ance is regarded with the API of the formulation.
AZM, is highly distributed from serum to lung epithelium
lining fluid (ELF), the infection site of pathogens. Trans-
porter(s) expressed on lung epithelial cells may contribute
to the distribution of the compounds to the ELF. The mech-
anisms of macrolides distribution are not still well known.
However, Togami et al. [9] reported that AZM, Clarithro-
mycin and Telithromycin, antibiotics are transported from
plasma to ELF by MDR1 of lung epithelial cells.
The significance of the stereochemical consideration in
the area of antimicrobial agents is relevantwhen the alteration
of any of the chiral centres results in a marked or total loss of
activity [10, 12]. As reported previously, AZM was recently
characterized as a new chiral selector with many stereogenic
centers and different functional groups (like other macrol-
ides, glycopeptides, ansamycins, and aminoglycosides),
which allow for multiple interactions with the analyte
enantiomeric molecules, resolving a wide range of enanti-
omers with very high selectivities [6]. These may explain the
difference on the distribution process of both formulations
assayed. The large difference obtained in favor of AZM-R-
(+1586 and 122% for AUC and𝐶max , resp.) may be due by the
selective binding to a “balanced chiral” AZM formulation
to the transporters towards the lung tissue (biophase)
(Figure 3).
The promiscuous binding of pharmaceutical drugs and
the transporter-mediated uptake into cells was recently
described by Kell et al. [12]. Probably in a racemic generic
formulation of multiple chiral molecules (as AZM), a mini-
mal deficiency on themanufacture processmay cause a chiral
imbalance of the API with the consequent difference on distr-
ibution (transporters-mediated uptake into cells) and antimi-
crobial activity. Specifically the fit of the enantiomers to the
different transporters/and receptor surface may be different
and the binding energies of the interaction may also differ.
Reports by Zuluaga et al. [14] and Vesga et al. [18] dem-
onstrated in vivo the no therapeutic equivalence of some
generic drugs using multiple chiral antibiotics like vanco-
mycin and gentamicin, in murine model. Interestingly those
authors, based on an article reported by Henderson and
Esham [19], stated that to approve generic versions of inno-
vator (reference) products, comparative preclinical or clinical
safety and/or efficacy studies are not required, assuming that
generics, by pharmaceutical equivalence or bioequivalence
studies, would generate similar outcomes to those obtained
with the innovator API.
4. Conclusions
In this paper have been assessed the serum exposure and lung
distribution of two commercial AZM formulations, in a pre-
clinical study in a healthy mice validated model. Differences
on the absorption process were not found, however; marked
modifications on the distribution process were eloquent. The
results obtained in this trial could partially explain the lack
of efficacy of some generic formulations AZM-based. Since
identical serum concentrations do not reflect the AZM tissue
distribution when compared AZM-R- with a generic formu-
lation, perhaps drug regulatory agencies need to discuss this
issue to complement the bioequivalence studies with a tissue
distribution trial in a validated primary species (mice)model.
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